File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel for Patients with Inoperable Pancreatic Cancer: Experience at a Single Oncology Centre

TitleGemcitabine Plus Nanoparticle Albumin-bound Paclitaxel for Patients with Inoperable Pancreatic Cancer: Experience at a Single Oncology Centre
Authors
KeywordsNeoplasm metastasis
Pancreatic neoplasms
Paclitaxel
Deoxycytidine/ analogs & derivatives
Issue Date2020
PublisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkjr.org
Citation
Hong Kong Journal of Radiology, 2020, v. 23 n. 1, p. 27-33 How to Cite?
AbstractObjective: To review the outcomes of gemcitabine plus nanoparticle albumin-bound (nab)-paclitaxel for patients with inoperable pancreatic cancer. Methods: The data of patients treated with this regimen at a single oncology centre in Hong Kong between December 2014 and December 2017 were retrospectively reviewed. Patient data assessed included serial tumour markers (carbohydrate antigen 19-9 and/or carcinoembryonic antigen) and ultrasound, computed tomography, or positron emission tomography-computed tomography scans. The primary objective was to evaluate progression-free and overall survival. The secondary objective was to evaluate the rate of treatment-related toxicities. All adverse events were graded with the Common Terminology Criteria for Adverse Events version 5. Results: The data of a total of 35 patients were analysed. The median age was 61 years and the majority (77%) had stage IV disease. Histological diagnosis was available in 74% of patients. The median number of cycles received was three. A total of 31% of patients required dose reduction of nab-paclitaxel. Median progression-free survival was 4.9 months (95% confidence interval [CI] = 3.4-6.4), and median overall survival was 7.5 months (95% CI = 5.6-9.4). Overall, 51% of patients received second-line or third-line chemotherapy following disease progression. Grade ≥3 neutropoenia occurred in 29% of patients and febrile neutropoenia in 6%. Grade ≥3 peripheral neuropathy occurred in 9% of patients. Conclusion: Gemcitabine plus nab-paclitaxel doublet chemotherapy is an effective and safe treatment for inoperable pancreatic cancer. Data from our centre are comparable to literature published to date. However, prognosis remains poor for this disease.
Persistent Identifierhttp://hdl.handle.net/10722/294036
ISSN
2015 SCImago Journal Rankings: 0.113
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLee, TY-
dc.contributor.authorLam, MHC-
dc.contributor.authorCheung, KM-
dc.contributor.authorCheng, HC-
dc.contributor.authorNgan, RKC-
dc.contributor.authorWong, KH-
dc.date.accessioned2020-11-23T08:25:26Z-
dc.date.available2020-11-23T08:25:26Z-
dc.date.issued2020-
dc.identifier.citationHong Kong Journal of Radiology, 2020, v. 23 n. 1, p. 27-33-
dc.identifier.issn2223-6619-
dc.identifier.urihttp://hdl.handle.net/10722/294036-
dc.description.abstractObjective: To review the outcomes of gemcitabine plus nanoparticle albumin-bound (nab)-paclitaxel for patients with inoperable pancreatic cancer. Methods: The data of patients treated with this regimen at a single oncology centre in Hong Kong between December 2014 and December 2017 were retrospectively reviewed. Patient data assessed included serial tumour markers (carbohydrate antigen 19-9 and/or carcinoembryonic antigen) and ultrasound, computed tomography, or positron emission tomography-computed tomography scans. The primary objective was to evaluate progression-free and overall survival. The secondary objective was to evaluate the rate of treatment-related toxicities. All adverse events were graded with the Common Terminology Criteria for Adverse Events version 5. Results: The data of a total of 35 patients were analysed. The median age was 61 years and the majority (77%) had stage IV disease. Histological diagnosis was available in 74% of patients. The median number of cycles received was three. A total of 31% of patients required dose reduction of nab-paclitaxel. Median progression-free survival was 4.9 months (95% confidence interval [CI] = 3.4-6.4), and median overall survival was 7.5 months (95% CI = 5.6-9.4). Overall, 51% of patients received second-line or third-line chemotherapy following disease progression. Grade ≥3 neutropoenia occurred in 29% of patients and febrile neutropoenia in 6%. Grade ≥3 peripheral neuropathy occurred in 9% of patients. Conclusion: Gemcitabine plus nab-paclitaxel doublet chemotherapy is an effective and safe treatment for inoperable pancreatic cancer. Data from our centre are comparable to literature published to date. However, prognosis remains poor for this disease.-
dc.languageeng-
dc.publisherHong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkjr.org-
dc.relation.ispartofHong Kong Journal of Radiology-
dc.rightsHong Kong Journal of Radiology. Copyright © Hong Kong Academy of Medicine Press.-
dc.subjectNeoplasm metastasis-
dc.subjectPancreatic neoplasms-
dc.subjectPaclitaxel-
dc.subjectDeoxycytidine/ analogs & derivatives-
dc.titleGemcitabine Plus Nanoparticle Albumin-bound Paclitaxel for Patients with Inoperable Pancreatic Cancer: Experience at a Single Oncology Centre-
dc.typeArticle-
dc.identifier.emailNgan, RKC: rkcngan@hku.hk-
dc.identifier.authorityNgan, RKC=rp02371-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.12809/hkjr2017076-
dc.identifier.scopuseid_2-s2.0-85086113434-
dc.identifier.hkuros319719-
dc.identifier.volume23-
dc.identifier.issue1-
dc.identifier.spage27-
dc.identifier.epage33-
dc.identifier.isiWOS:000524980900006-
dc.publisher.placeHong Kong-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats